NL-OMON23894招募中不适用
Kidney FuNction in people receiving Gender affirming Hormone Therapy
Dr. D.H. van Raalte Department of Endocrinology, VUMC/AMC De Boelelaan 1117, 1081 HV, Amsterdam E-mail: d.vanraalte@amsterdamumc.nl0 个研究点目标入组 40 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- •-Diagnosed with gender dysphoria according to DSM-V (transmen or transwomen)
- •-Age between 18 and 30 years
- •-Expected to start cross-sex hormone treatment in the upcoming month
排除标准
- •A potential subject who meets any of the following criteria will be excluded from participation in this study:
- •-Current use of sex hormones
- •-Participation in other studies
- •-Concomitant use of medication (specifically: blood pressure lowering products, anti-depressants, anti-psychotic agents or medication prescribed for the treatment of attention deficit hyperactivity disorder),
- •-Known kidney disease (eGFR < 60 ml/min; UACR > 2,5 mg/mmol)
- •-Diabetes mellitus
- •-A history of cardiovascular disease (myocardial infarction; cardiac surgery or revascularization, unstable angina, heart failure, transient ischemic attack, cerebrovascular disease or a previously undiagnosed arrhythmia
- •-Known iodine related allergies
研究者
相似试验
招募中
不适用
Kidney fuNction in people receiving Gender Affirming Hormone TherapyNL-OMON52715Vrije Universiteit Medisch Centrum40
招募中
不适用
Consideration the changes of renal function for renal cell carcinoma patients, administered the molecular target drugs: axitinib, sunitinib and sorafenibRenal cell carcinomaJPRN-UMIN000019393Dokkyo Medical University, Department of Urology30
招募中
不适用
Examination of the effects on renal function and prognosis of various diuretics for liver cirrhosisiver cirrhosisJPRN-UMIN000040179Hokkaido University400
进行中（未招募）
1 期
Evaluation of the impact of renal function on the pharmacokinetics of hydroxyurea (Siklos®) in patients with sickle cell disease with normal renal function, with hyperfiltration, or with renal failure. DARH studySiklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults, adolescents and children older than 2 years suffering from symptomatic sickle cell syndrome.MedDRA version: 17.1Level: LLTClassification code 10040643Term: Sickle cell crisisSystem Organ Class: 100000004851EUCTR2014-005033-31-FRAddmedica S.A.S
已完成
4 期
Study of Assessment for Kidney function by Urinary microalbumin in RAndomized TrialHypertension with diabetic nephropathyJPRN-UMIN000001247The University of Tokyo Graduate School of Medicine500